# A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea

> **NCT07018544** · — · ENROLLING_BY_INVITATION · sponsor: **Novo Nordisk A/S** · enrollment: 840 (estimated)

## Conditions studied

- Obesity and Overweight

## Interventions

- **OTHER:** semaglutide

## Key facts

- **NCT ID:** NCT07018544
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-11-19
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-02-28
- **Target enrollment:** 840 (ESTIMATED)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07018544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07018544, "A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07018544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*